73 results
COVID-19: ICU Guidelines for the Non-Intensivist
Infection Control
Risk Factors for Severe Disease
Initial Laboratory Workup
COVID-19 Specific Medications
Respiratory
Cardiac
Hematologic
Neuro/Sedation

#COVID19 #ICU
Non-Intensivist Infection ... Control Risk Factors ... Respiratory Cardiac Hematologic ... #COVID19 #ICU #criticalcare
Central Venous Catheter site selection - Clinical Decision Aid
IJ vs Subclavian vs Supraclavicular vs Femoral by
Femoral by ease and risk ... of infection, DVT ... #Management #CriticalCare ... Locations #Sites #Infections
Clostridium Dificile Risk by Antibiotic Class

Pooled and study-specific risk estimates of community-associated CDI risk by antibiotic
Clostridium Dificile Risk ... study-specific risk ... #CDifficile #Infection ... #Association #Pharmacology ... #Class #Risk #Clindamycin
Pulmonary Embolism Treatment
Systemic Thrombolysis
 - Exclude contraindications.
 - Indications:
   - Massive PE (definite indication)
submassive PE (risk ... 50mg IV) - 2% risk ... of ICH and 6% risk ... who are higher risk ... AcutePE #Management #CriticalCare
Pulmonary Embolism - Risk Stratification and Prognostication based on scores and clinical features

 • Bova score
Pulmonary Embolism ... - Risk Stratification ... @nickmmark #Pulmonary ... #Embolism #Risk ... stratification #criticalcare
Tranexamic Acid - Indications and Pharmacology
Pharmacokinetics:
 • MOA: Inhibits plasminogen activation to plasmin & inhibits fibrinolysis
Indications and Pharmacology ... Hypotension with rapid injection ... fatigue; Increases risk ... #Indications #Pharmacology ... #hematology
Myelodysplastic Syndrome (MD) - Diagnosis and Management Summary
myelo (marrow) -dys- (abnormal) -plastic (shape) = funny-shaped cells
diagnosis and risk-stratification ... • Risks: infection ... Management #treatment #hematology
SGLT2 Inhibitors - Pharmacology Summary
Mechanisms of Action: Inhibits SGLT2 (sodium/glucose cotransporter 2) in the proximal tubule,
SGLT2 Inhibitors - Pharmacology ... Jardiance) - Best risk ... mortality in high risk ... hypovolemia) • GU infections ... Canagliflozin ↑ risk
Hydroxychloroquine - Risks and Benefits in Lupus
Benefits:
↓ Disease activity, ↓ Flare, ↓ Damage, ↓ Corticosteroid dose,
Thrombosis, ↓ Severe infection ... Cardiovascular risk ... deficiency [(limited) risk ... Benefits #Lupus #pharmacology ... #sideeffects #rheumatology
GLP-1 Receptor Agonists - Pharmacology Summary
Mechanisms of Action: Stimulate glucose-dependent insulin release from the pancreas (GLP-1
Receptor Agonists - Pharmacology ... /day or weekly injection ... outcomes in high risk ... effect) • May ↑ risk ... Receptor #Agonists #Pharmacology